3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Breast Neoplasms
81
Carcinoma, Non-Small-Cell Lung
76
Neoplasms
71
Ovarian Neoplasms
68
Neoplasm Metastasis
30
Fallopian Tube Neoplasms
30
Carcinoma, Ovarian Epithelial
29
Lung Neoplasms
26
Unspecified Adult Solid Tumor, Protocol Specific
24
Triple Negative Breast Neoplasms
20
Endometrial Neoplasms
20
Esophageal Neoplasms
18
Stomach Neoplasms
16
Colorectal Neoplasms
14
Squamous Cell Carcinoma of Head and Neck
13
Head and Neck Neoplasms
13
Solid Tumors
12
Small Cell Lung Carcinoma
10
Melanoma
10
Pancreatic Neoplasms
9
Uterine Cervical Neoplasms
8
Prostatic Neoplasms
8
Lymphoma, Non-Hodgkin
8
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma
8
Carcinoma, Renal Cell
8
Carcinoma
8
Brenner Tumor
8
Urinary Bladder Neoplasms
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Interventions
tremelimumab
3
durvalumab
3
Ipilimumab
3
pembrolizumab
2
Nivolumab
2
Carboplatin
2
poly ICLC
1
osimertinib
1
lenvatinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Vaccination
1
Peptides
1
Pemetrexed
1
Paclitaxel
1
Monophenol Monooxygenase
1
Melphalan
1
Docetaxel
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Paclitaxel
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled